Better Pharma Buy: Viatris vs. Pfizer
Pfizer (NYSE: PFE) and (NASDAQ: VTRS) have a common past. That's because Viatris came about a few years ago when Pfizer's Upjohn business merged with generic drug giant, Mylan. Since, their share performance paths have diverged. Pfizer stock soared through the earlier days of the pandemic as it took leadership of the vaccine and treatment markets. Meanwhile, Viatris shares have steadily declined.
Today, both stocks seem to be trading at reasonable valuations. They offer dividends and future products that could drive some growth. But which of these companies represents the better buy right now? Let's find out.
Viatris delivers billions of dollars in revenue annually thanks to a portfolio of well-known generics and branded medicines. Many of its drugs are widely used to treat common problems -- from allergies to high blood pressure. But, with the exception of cholesterol drug Lipitor, these products generally don't bring in blockbuster revenue.
Source Fool.com
